Trial design challenges when <font color="blue">combining_1</font> <font color="blue">medication_1</font> <font color="blue">and_1</font> <font color="blue">parent_1</font> <font color="blue">training_1</font> in children with <font color="blue">pervasive_1</font> <font color="blue">developmental_1</font> <font color="blue">disorders_1</font> <font color="blue">._1</font> <font color="blue">
<br>
<br>_1</font> This paper presents the rationale for a 24-week , randomized trial designed to test whether risperidone plus structured parent training would be superior to risperidone only on measures of <font color="blue">noncompliance_3</font> <font color="blue">,_3</font> <font color="blue">irritability_3</font> <font color="blue">and_3</font> <font color="blue">adaptive_3</font> <font color="blue">functioning_3</font> <font color="blue">._3</font> In this model , <font color="blue">medication_2</font> <font color="blue">reduces_3</font> <font color="blue">tantrums_5</font> <font color="blue">,_5</font> <font color="blue">aggression_5</font> <font color="blue">and_5</font> <font color="blue">self_5</font> <font color="blue">-_5</font> <font color="blue">injury_5</font> <font color="blue">;_5</font> <font color="blue">parent_1</font> <font color="blue">training_1</font> <font color="blue">promotes_3</font> <font color="blue">improvement_4</font> <font color="blue">in_4</font> <font color="blue">noncompliance_5</font> <font color="blue">and_5</font> <font color="blue">adaptive_5</font> <font color="blue">functioning_5</font> <font color="blue">._5</font> Thus , <font color="blue">medication_1</font> <font color="blue">and_1</font> <font color="blue">parent_1</font> <font color="blue">training_1</font> <font color="blue">target_1</font> <font color="blue">related_1</font> <font color="blue">,_1</font> <font color="blue">but_1</font> <font color="blue">separate_1</font> <font color="blue">,_1</font> <font color="blue">outcomes_1</font> <font color="blue">._1</font> At week 24 , the medication was gradually withdrawn to determine whether subjects in the combined treatment group could be managed on a lower dose or off <font color="blue">medication_1</font> <font color="blue">without_1</font> <font color="blue">relapse_2</font> <font color="blue">._2</font> Both <font color="blue">symptom_5</font> <font color="blue">reduction_5</font> <font color="blue">and_4</font> <font color="blue">functional_5</font> <font color="blue">improvement_5</font> are important clinical treatment targets . Thus , experimental evidence on the beneficial effects of <font color="blue">combining_1</font> <font color="blue">pharmacotherapy_1</font> <font color="blue">and_1</font> <font color="blue">exportable_1</font> <font color="blue">behavioral_1</font> <font color="blue">interventions_1</font> is needed to guide clinical practice .